Novartis Pays $125M for Sironax Blood-Brain Barrier Platform
The deal gives Novartis a way to move large-molecule drugs into the central nervous system, at a time when its neuroscience pipeline has suffered setbacks.
Novartis is paying Sironax $125 million to gain control of a drug-delivery platform designed to carry large molecules across the blood-brain barrier, according to Fierce Biotech, BioPharma Dive, and MedCity News. The platform is intended to transport a range of drug modalities into the central nervous system, addressing a key obstacle for neuroscience treatments.
BioPharma Dive reports that the deal gives Novartis global rights to the technologyanding that Sironax will use the proceeds to advance three candidates it calls 'best-in-class' potential. Fierce Biotech frames the payment as Novartis taking up an option on the platform, while MedCity News describes it as an acquisition; otherwise the sources agree on the $125 million price and the platform's purpose.
The deal comes as Novartis weathers several pipeline setbacks, including recent trial failures for neuroscience drug candidates, notes MedCity News. With this platform, Novartis gains a way to get drugs past the protective barrier that often blocks them from reaching targets in the brain.
Sources · 3
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.